Novo Nordisk A/S Class B Common Stock

As of the most recent data (June 2026), NONOF shows a common stock of $450M. That compares with $450M in the prior-year period — up 0.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NONOF's common stock is now $450M (was $450M) — essentially flat versus a year earlier. Pairing that YoY change with peer averages gives a clearer picture of whether Novo Nordisk A/S Class B is outperforming or lagging.

Tracking NONOF's common stock over time shows whether Novo Nordisk A/S Class B is scaling, shrinking, or reshaping that part of the business. The current reading is $450M That compares with $450M in the prior-year period — up 0.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this common stock page, Stockcircle has Novo Nordisk A/S Class B's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $450M) with ownership activity and broader fundamentals.

Novo Nordisk A/S Class B's common stock is $450M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.